Global Fragile X Syndrome Market

Report ID : 1065 | Published : 2022-08-16 | Pages: 140 | Format: PDF/EXCEL

Fragile X syndrome is a hereditary condition that causes a range of neurological problems, including cognitive impairment and learning disabilities. Males are more affected compare to females by this disorder. It causes delayed development of speech and language by age 2. Affected children may develop attention deficit disorder; about one-third of individuals may develop autism, and in about 15% of male and 5% of female seizure occurs. Most males and about half of females with fragile X syndrome have characteristic physical features that become more prominent with age. These features include large ears, a long and narrow face, unusually flexible fingers, flat feet, a prominent jaw and forehead, and in males, enlarged testicles after puberty. It is estimated that approximately 1 in 2500-4000 males and 1 in 7000-8000 females.
The global Fragile X syndrome market is segmented on the basis of treatment and geography. On the basis of treatment, the global Fragile X syndrome is further segmented into sedatives, muscle relaxants, antipsychotics, and other. Currently, there is no approved treatment for Fragile X Syndrome. However, treatment and intervention are focused to improve the lives of affected individuals. The majority of pipeline molecules (gaboxadol, etc.) for the treatment of Fragile X Syndrome are currently in phase 2 of development are expected to come into the market in the forecast period. An increase in incidence and prevalence of Fragile X Syndrome expected to boost the growth of the market in forecast period. In addition to it, ongoing clinical trials and growing licensing and acquisition deals will further drives the growth of the market. However, stringent government regulation, complex disease mechanism, and disappointing results of promising pipeline molecules hampers the development of the Fragile X syndrome market during the forecast period. Furthermore, a lack of awareness among people regarding genetic disorders restrains the growth of the market.
At regional level, the global Fragile X syndrome market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, North America followed by Europe is major contributor for the global Fragile X syndrome market. This is because strong clinical pipeline, increasing research and drug development activities, presence of major players, and presence of developed healthcare infrastructure propels the growth of the market in the region. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace in upcoming year. Countries such as Japan, India and China are major contributors for this market. Emerging and huge population base countries such as China and India offers tremendous market opportunities for the Fragile X syndrome market.
Some of the market players leading the global Fragile X syndrome market include Marinus pharmaceuticals, Ovid therapeutics, Kareus Therapeutics, Bellus health Inc., AMO pharmaceuticals, Eli Lilly & Company, Neuren pharmaceuticals, Anavex Life Sciences Corp., and Zynerba Pharmaceuticals, Inc.

  • Marinus pharmaceuticals
  • Ovid therapeutics
  • Kareus Therapeutics
  • Bellus health Inc
  • AMO pharmaceuticals
  • Eli Lilly & Company
  • Neuren pharmaceuticals
  • Anavex Life Sciences Corp
  • Zynerba Pharmaceuticals, Inc
  • Other Prominent Player with Pipeline Product Portfolio

Global Fragile X Syndrome Market Outlook and Pipeline Analysis

  • Phase I
  • Phase II
  • Phase III

Major Qualitative Insights

  • Industry Overview
  • Key Market Trends
  • Market Drivers and Challenges
  • Fragile X Syndrome Market Size and Forecast
  • Clinical Trial/Pipeline Analysis
  • Disease Epidemiology in key countries
  • Key News/Industry Activities
  • Major Mergers & Acquisition
  • Competitive Landscape
  • Company Overview
    • Financial Performance
    • Key Development
    • Latest Strategic Developments


InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..